The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PAZONET: Results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE)—NCT01280201.
Enrique Grande Pulido
Research Funding - GlaxoSmithKline
Daniel E. Castellano
No relevant relationships to disclose
Rocio Garcia-Carbonero
No relevant relationships to disclose
Alex Teule
No relevant relationships to disclose
Ignacio Duran
No relevant relationships to disclose
Jose Fuster
No relevant relationships to disclose
Isabel Sevilla
No relevant relationships to disclose
P. Escudero
No relevant relationships to disclose
Javier Sastre
No relevant relationships to disclose
Jaume Capdevila
No relevant relationships to disclose